AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

Core Insights - AIM ImmunoTech Inc. announced the publication of data from a Phase 1 study on its drug Ampligen® for early-stage triple-negative breast cancer (TNBC) [1] - The study was conducted at Roswell Park Comprehensive Cancer Center and results were published in The Journal for ImmunoTherapy of Cancer [1][2] Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen® being its lead product [4] - Ampligen® is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist, showing broad-spectrum activity in clinical trials [4] Study Findings - The principal investigator, Dr. Shipra Gandhi, expressed excitement over the promising results, noting the need for validation in larger studies [2] - AIM's CEO, Thomas K. Equels, highlighted that the study results suggest Ampligen can modify the tumor microenvironment and attract killer T-cells to TNBC tumors [2] - The data from this pilot study are consistent with previous findings in late-stage TNBC and other cancers [2] Future Directions - The company looks forward to collaborating with Roswell Park as the study progresses to Phase 2 [2] - The potential of Ampligen to work alongside various chemotherapy regimens and immune checkpoint inhibitors is emphasized [2]